IN8bio financials
$1.30+4.44%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating income | -$19.9M | -$30.7M | -$30.3M | -$28.5M | -$14.7M | -$8.6M |
| Net income | -$19.4M | -$30.4M | -$30.0M | -$28.5M | -$14.7M | -$10.3M |
| Net margin | — | — | — | — | — | — |
| Diluted EPS | $-4.44 | $-17.05 | $-30.00 | $-40.80 | $-44.10 | $-90.60 |
| EBITDA | -$18.9M | -$29.7M | -$28.5M | -$27.4M | -$13.9M | -$8.5M |
| Operating cash flow | -$12.7M | -$24.1M | -$23.3M | -$24.1M | -$13.5M | -$7.1M |
| Free cash flow | -$12.7M | -$24.3M | -$23.5M | -$24.1M | -$13.8M | -$7.1M |
| Diluted shares | 4.4M | 1.8M | 1.0M | 0.7M | 0.3M | 0.1M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $27.1M | $11.1M | $21.3M | $18.2M | $37.0M | $18.0M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $295.0K | $989.0K | $1.2M | $1.5M | $661.0K | $174.0K |
| Total assets | $32.3M | $20.9M | $33.7M | $33.0M | $42.2M | $20.9M |
| Total liabilities | $4.7M | $6.5M | $8.8M | $10.3M | $4.0M | $2.6M |
| Shareholders' equity | $27.6M | $14.5M | $24.9M | $22.7M | $38.2M | -$16.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology